TMJ 'dysfunction' - Health implications

The University of Buffalo, New York has issued a press release reporting the results of their 'landmark pilot study of Liberation Treatment' and has stated that 'correcting CCSVI with venous angioplasty was of no value for treating MS."

They also released a YouTube video which claims that it may be 'potentially harmful' and advises 'caution strongly agaist the general acceptance of this invasive procedure for MS patients'.

In response Ashton Embry writes:

The Actual Data from PREMiSe Do Not Support the Highly Publicized, Anti-CCSVI Claims and Warnings of the University of Buffalo Researchers.

Ashton Embry, DIRECT-MS, April, 2013

Quick Summary
"The actual data from the PREMiSe Trial do not support the highly publicized claim that CCSVI correction by angioplasty is not of value for MS and may worsen disease activity. In sharp contrast, the data suggests that CCSVI correction may well be of substantial value for MS. The misleading claims made by University of Buffalo researchers are based on irrelevant data from the failed Phase 2 portion of the trial in which no one had their CCSVI corrected. The anti-CCSVI bias and baseless claims may be explained by the conflicts of interest."

Executive Summary
"University of Buffalo (UB) MS researchers put out a press release and Youtube video with claims that the Phase 2 portion (controlled, randomized and double blind) of their PREMiSe clinical trial demonstrated that CCSVI correction (restoration of >75% venous blood flow from the brain) by means of venous angioplasty, was not of value for MS and was possibly harmful.

An inspection of the PREMiSe data on the poster presented by UB researchers at the recent AAN convention in San Diego reveals the following
1) All the subjects in the open label, Phase 1 portion of the PREMiSe trial had their CCSVI was corrected (>75% blood flow restored by venous angioplasty). They had very good clinical results over the 6 months with no relapses and only 2 new lesions among the ten subjects.
2) The controlled and blinded Phase 2 portion of the PREMiSe trial was a failure because those receiving angioplasty did not have their CCSVI corrected (i.e. they did not have their blood flow restored to >75%)."

Read the full report here http:http://www.direct-ms.org/sites/default/files/Embry%20Premise%20Evaluation%20April%202013.pdf